A share price of Novabay Pharmaceuticals Inc [NBY] is currently trading at $0.15, down -1.40%. An important factor to consider is whether the stock is rising or falling in short-term value. The NBY shares have gain 3.93% over the last week, with a monthly amount drifted -9.31%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 30, January 2024, NovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based Sales. In a post published today on Yahoo Finance, NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com. A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022. In addition, of the more than 13,000 customer reviews across all online channels, Avenova Spray averaged a 4.5-star overall rating.
From an analyst’s perspective:
Novabay Pharmaceuticals Inc [AMEX: NBY] stock has seen the most recent analyst activity on September 18, 2019, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $1.10. Previously, H.C. Wainwright reaffirmed its Buy rating on July 06, 2018, and kept the price target unchanged to $4. On November 15, 2017, Laidlaw reiterated its Buy rating and revised its price target to $8 on the stock. ROTH Capital started tracking the stock assigning a Buy rating and suggested a price target of $5.50 on June 05, 2017. Laidlaw initiated its recommendation with a Buy and recommended $10 as its price target on March 27, 2017. Rodman & Renshaw started tracking with a Buy rating for this stock on February 06, 2017, and assigned it a price target of $6. In a note dated March 07, 2016, Maxim Group downgraded an Hold rating on this stock.
Novabay Pharmaceuticals Inc experienced fluctuations in its stock price throughout the past year between $0.12 and $2.21. Currently, Wall Street analysts expect the stock to reach $4 within the next 12 months. Novabay Pharmaceuticals Inc [AMEX: NBY] shares were valued at $0.15 at the most recent close of the market. An investor can expect a potential return of 2566.67% based on the average NBY price forecast.
Analyzing the NBY fundamentals
Trailing Twelve Months sales for Novabay Pharmaceuticals Inc [AMEX:NBY] were 14.64M which represents -14.66% decline. Gross Profit Margin for this corporation currently stands at 0.54% with Operating Profit Margin at -0.1%, Pretax Profit Margin comes in at -0.94%, and Net Profit Margin reading is -1.08%. To continue investigating profitability, this company’s Return on Assets is posted at -1.22, Equity is -1.8 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.43.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.1431 points at the first support level, and at 0.1381 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.1559, and for the 2nd resistance point, it is at 0.1637.
Novabay Pharmaceuticals Inc [NBY] reported earnings per share of -$0.37 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.4/share, meaning a difference of $0.03 and a surprise factor of 7.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$1.27 per share as compared to estimates of -$0.55 per share, a difference of -$0.72 representing a surprise of -130.90%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Novabay Pharmaceuticals Inc [AMEX:NBY] is 1.80. On the other hand, the Quick Ratio is 1.03, and the Cash Ratio is 0.76. Considering the valuation of this stock, the price to sales ratio is 0.07, the price to book ratio is 0.19.
